read the latest news about Venous Thromboembolism related to PE

What‘s new about VTE?

Discover the latest news from international experts about Venous Thromboembolism.

Read our latest news about VTE

Boston Scientific shares its latest news about Venous Thromboembolism (VTE) related to Pulmonary Embolism (PE). Most recent news are listed at the top of this page.

The REAL-PE Analysis (October 2023)

The REAL-PE Analysis is the largest real-world and near real-time dataset evaluating advanced therapies for PE patients. The results? Patients treated with the EKOS™ system had statistically significant lower rates of major bleeding and intracerebral haemorrhage than patients treated with Inari Medical’s FlowTriever™ system.

When is the right time for PE Interventional Treatment? (May 2023)

Hear from international experts while they share the latest advancements on Pulmonary Embolism, its treatment options and preventive measures including the importance of implementing the role of a dedicated response team. (Time 1 hour 17 min)

ACVC Congress 2023 (March 2023)

Watch now the symposium “Treating PE – Keep it simple” held at the ESC Acute CardioVascular Care. Prof. Stavros Konstantinides and other global leading experts such as Prof. Daniel Dürschmied, Dr. Lukas Hobohm and Prof. Andrew discuss the strong clinical evidence of EKOS™ as an easy and safe system to treat Pulmonary Embolism. (Time 44 min)

Interview with Prof. Pruszczyk on Acute Pulmonary Embolism clinical consensus statement (2022)

Watch now to hear Prof. Pruszczyk, one of the authors from the European Society of Cardiology (ESC) working group address: why this topic is important to the working group (time 3 min), what are the key takeaways (time 3 min), and the call for action in treatment of Acute PE (Time 2 min).

The RETHRO study presented at LINC (June 2022)

Watch now Prof. Kucher presenting the RETHRO study (2017-2021) where EKOS ultrasound accelerated thrombolysis has been used to treat patients with intermediate-high and high-risk Pulmonary Embolism at LINC 2022. (Time 9 min)

Catheter Lysis with EKOS in Pulmonary Embolism at LINC (June 2022)

Hear from Prof. Sharp while he shares case base presentation including clinical evidence to date for Pulmonary Embolism treatment using EKOS at LINC 2022. (Time 16 min)

The Zurich Pathway presented at LINC (June 2022)

Hear from Prof. Nils Kucher share Zurich Pulmonary Embolism patient pathway for intermediate-high risk and high-risk patients, with a case base discussion. And some data showing the effect of ultrasound in-vitro. (Time 7 min)

EXPERT-PE Conference (2022)

Boston Scientific hosted a symposium dedicated to Pulmonary Embolism during the EXPERT-PE Conference in Leiden on Saturday, October 15th. Our session on "EKOS Endovascular System: the most studied interventional PE device, what questions remain unanswered" was moderated by Prof. Erik Klok and other expert leaders such as Prof. Konstantinides and Prof. Sharp were highly involved in the discussion sharing their best practices around the treatment of PE. (Time 36 min)


Acute Pulmonary Embolism Consensus Statement by ESC & EAPCI (2022)

The European Society of Cardiology and the Acute European Association of Percutaneous Cardiovascular Interventions have shared a clinical consensus statement on the treatment of Pulmonary Embolism.

The paper, authored by a team of PE expert leaders, serves as a practical guide for catheter directed therapies, confirming their clinical success, complementary to the formal guidelines when approaching the treatment of PE.

EKOS Pulmonary Embolism Forum 2022 Hong Kong

Boston Scientific is committed to helping practitioners to learn more about Pulmonary Embolism: how to diagnose it, how to treat it, and when it’s right to intervene.
Hear the expert Pr. Andrew Sharp discussing on the effectiveness of EKOS to reverse RV dysfunction and hemodynamic instability, and its association with low risk of bleeding and mortality in intermediate-high to high-risk Pulmonary Embolism patients. (Time 24 min)


KNOCOUT PE Registry Prospective Cohort: 3-Month Data (2021)

KNOCOUT PE registry represents the single largest prospective data set in interventional PE treatment to-date, adding evidence to the already most studied device in the PE space. The registry included a wide range of patients with intermediate-high and high-risk PE, showing that contemporary clinical practices are moving to low-dose, shorter duration OPTALYSE protocols and with it comes the benefit of both sustained efficacy and an improved safety profi


Hi-PEITHO Trial: Patient enrollment gets underway

The largest randomised controlled trial on Intervention vs Anticoagulation in Pulmonary Embolism. 

“We are pleased to see the official start to the HI-PEITHO trial with the first patient enrollment. HI-PEITHO is the largest, most rigorous trial in the PE space intended to address critical gaps in PE clinical evidence. This trial reflects Boston Scientific’s investment and commitment to providing the highest level of scientific evidence to ultimately help guide clinical practice.”

Ekos™ Endovascular System

Higher-risk Pulmonary Embolism Thrombolysis Study (October 2020)

Introducing the Hi-PEITHO randomised controlled trial for the EKOS™ Endovascular System. The study is the first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for the treatment of pulmonary embolism. (Time 3 min)

Pulmonary Embolism and COVID-19 | How to handle this new paradigm? (April 2020)

A group of European opinion-leaders in Pulmonary Embolism (PE) came together (virtually) in April 2020 to discuss the connection between PE and COVID-19. (Time 1 hour 26 min)

Expand your education about endovascular interventions

Learn about Boston Scientific blended learning programmes and on-demand training resources available to you in EDUCARE.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.